EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk Factors and Treatment Outcome Analysis Associated with Second-Line Drug-Resistant Tuberculosis

Muralidhar Aaina, Kaliyaperumal Venkatesh, Brammacharry Usharani, Muthukumar Anbazhagi, Gerard Rakesh, Muthaiah Muthuraj

Journal of Respiration · 28.12.2021 · 2 (1) · 1-12

DOI: 10.3390/jor2010001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Respiration, online erschienen am 28.12.2021. Verfasst von Muralidhar Aaina und 5 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study aimed at analyzing the treatment outcomes and risk factors associated with fluoroquinolone drug resistance having mutations in the gyrA and gyrB genes. A total of 258 pulmonary tuberculosis samples with first-line drug-resistant (H, R, or HR) were subjected to GenoType MTBDRsl assay for the molecular detection of mutations. Among the 258 samples, 251 were drug-resistant tuberculosis and seven were sensitive to all first-line TB drugs. Out of 251 DR-TB cases, 42 cases were MDR TB, 200 were INH mono-resistant and nine cases were RIF mono-resistant tuberculosis. Out of 251 DR-TB cases performed with a MTBDRsl assay, 14 had Pre-XDR-FQ, one patient had pre-XDR-SLID, one had extensively drug-resistant tuberculosis (XDR-TB) and 235 cases were sensitive to both FQ and SLID drugs. The study group had a mean average of 42.7 ± 16.4 years. The overall successful treatment outcomes among the MDR, INH mono-resistant, and pre-XRD patients were 70.6%, 82.0%, and 51%, respectively. The percentage of risk for the unfavorable outcomes in the pre-XDR, INH -mono-resistant, and XDR cases were 113.84% increased risk with RR 2.14; 95% CI 0.7821–5.8468. The independent risk factor associated with the unfavorable outcomes to failure was 77.78% increased risk with RR 1.78; 95% CI 0.3375–9.3655. Logistic regression analysis revealed that the percentage relative risk among MDR-TB patients for gender, male (RR: 1.85), age ≥ 61 years (RR: 1.96), and diabetics (RR: 1.05) were 84.62%, 95.83%, and 4.76%, respectively. The independent risk factors associated with INH mono-resistant cases of age 16–60 (RR: 1.86), ≥61 year (RR: 1.18), and treated cases (RR: 5.06). This study presaged the significant risk of INH mono-resistant, pre-XDR, and MDR among males, young adults, diabetics, and patients with previous treatment failure. Timely identification of high-risk patients will give pronounced advantages to control drug resistance tuberculosis diseases.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Aaina, M., Venkatesh, K., Usharani, B., Anbazhagi, M., Rakesh, G., & Muthuraj, M. (2021). Risk Factors and Treatment Outcome Analysis Associated with Second-Line Drug-Resistant Tuberculosis. Journal of Respiration, 2(1), 1-12. https://doi.org/10.3390/jor2010001

Vancouver

Aaina M, Venkatesh K, Usharani B, Anbazhagi M, Rakesh G, Muthuraj M. Risk Factors and Treatment Outcome Analysis Associated with Second-Line Drug-Resistant Tuberculosis. Journal of Respiration. 2021;2(1):1-12. doi:10.3390/jor2010001

BibTeX
@article{Aaina2021,
  author = {Aaina, Muralidhar and Venkatesh, Kaliyaperumal and Usharani, Brammacharry and Anbazhagi, Muthukumar and Rakesh, Gerard and Muthuraj, Muthaiah},
  title = {Risk Factors and Treatment Outcome Analysis Associated with Second-Line Drug-Resistant Tuberculosis},
  journal = {Journal of Respiration},
  year = {2021},
  volume = {2},
  number = {1},
  pages = {1--12},
  doi = {10.3390/jor2010001}
}
Kostenlos starten →